

Publications auxquelles l'Aretasc a participé en 2019

1500_PR - Pertuzumab (P) + trastuzumab (T) with or without chemotherapy both followed by T-DM1 in case of progression in patients with HER2-positive metastatic breast cancer (MBC) - The PERNETTA trial (SAKK 22/10), a randomized open label phase II study (SAKK, UNICANCER, BOOG) (ID 547) Esmo 2019 Berlin Germany

The CTS5 risk score overestimates the risk of late distant recurrences in high risk patients with HR positive breast cancer : a validation study using the TEAM and IDEAL trial :Iris Noordhoek, Erik J blok, Elma M-Klein Kranenbarg, Jean Michel Vannetzel.This work has been presented as an oral presentation at the ESMO Breast Cancer Conference on May 4th, 2019 in Berlin,Germany.

The Oncotype DX Breast Recurrence Score[®] test acknowledged with strong recommendation in the updated ASCO Guidelines 2019

Phare study :6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. Lancet 6 juin 2019.

Effectiveness and safety of Nivolumab in the treatment of lung cancer patients in France : Updated survival and subgroup analyses from the real- world EVIDENS study. : Barlesi F.1, Dixmier A.2, Debieuvre D.3, Raspaud C. Esmo 2019